Table 3.

Comparison of COAG and EU-PACT dose-initiation strategies among COAG study participants.

	All participants		Black participants		Nonblack participants
	Pharmacogenetic-guided dosing	Clinically guided dosing	Pharmacogenetic-guided dosing	Clinically guided dosing	Pharmacogenetic-guided dosing	Clinically guided dosing
Difference in total dose over first 3 days of therapy between EU-PACT and COAG strategies *
	(n=510)	(n=500)	(n=139)	(n=134)	(n=371)	(n=366)
Mean (SD), mg	4.8 (1.8)	2.5 (3.4)	6.4 (1.5)	0.1 (3.9)	4.2 (1.5)	3.4 (2.7)
Mean (SD) ratio of average initial dose to maintenance dose †
	(n=370)	(n=349)	(n=84)	(n=89)	(n=286)	(n=260)
COAG strategy	1.1 (0.4)	1.1 (0.4)	1.2 (0.5)	1.1 (0.3)	1.1 (0.4)	1.1 (0.4)
EU-PACT strategy	1.5 (0.5)	1.3 (0.6)	1.6 (0.6)	1.1 (0.4)	1.4 (0.5)	1.3 (0.6)

SD, standard deviation

^*For each COAG study participant (n=1,010), we first calculated the total dose over the first 3 days of therapy under the COAG and EU-PACT dose-initiation strategies. We then calculated the differences between strategies as the total dose under the EU-PACT strategy minus the total dose under the COAG strategy; a positive difference indicated a larger total dose under the EU-PACT dose-initiation strategy.

^†For each COAG study participant who achieved maintenance dose (n=719), we first calculated the total dose over the first 3 days of therapy under the COAG and EU-PACT dose-initiation strategies. We then divided the average dose over the first 3 days of therapy by the observed maintenance dose; a ratio of 1 indicated equality between the average initial dose and the maintenance dose.